Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs Strategy Inc. (MSTR) Price & Performance

Medpace Holdings IncTrade
Strategy Inc.Trade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs Strategy Inc. — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Strategy Inc. trades at $101 (market cap $35.47B). The key difference: Strategy Inc. is far larger — about 2.4× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals.

MEDPMSTR
Market Cap
$15.08B$35.47B
Sector
TechnologyTechnology
52-Week High
$620.59$426.40
52-Week Low
$308.88$82.31
Enterprise Value
$14.55B$50.50B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.

MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.

Strategy Inc.

MSTR trades at $97.77, up 3.08% today, but remains in a bearish technical trend with resistance at $98. The company shows concerning fundamentals with a -2,482% net income margin and negative cash flow from operations of -$67.24M in 2025. Recent earnings missed expectations in two of the last three quarters, though analyst consensus remains bullish with a $237.63 price target representing 143% upside potential from current levels.

While Wall Street maintains a Buy rating (62% of analysts), significant risks include extreme profitability challenges, volatile earnings history, and high debt levels. The stock's valuation appears disconnected from underlying business performance, trading at a low P/E of 5.3 but extremely high P/S of 57.4, suggesting investors are pricing in future growth that current operations don't support.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP

About Strategy Inc.

MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web

Read more on MSTR